Thioredoxin - 1 protects
against androgen receptor - induced redox vulnerability in castration - resistant prostate cancer.
Not exact matches
Researchers believed that galeterone could be effective
against CRPC because it disrupts the
androgen receptor signalling pathways that are involved in the cancer, and preclinical work has shown it is active
against the AR - V7 variant.
The new research found that on top of their known effects on cancer, Hsp90 inhibition also blocked production of abnormal forms of the
androgen receptor, stripping cancer cells of their defences
against hormone treatments.